• 15797 Citations
1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Alterations of signal transduction pathways play a significant role in the growth and metastasis of human cancers. One of our major focuses is the Her2/neu receptor tyrosine kinase, a member of the EGFR growth factor receptor family, which is gene amplified and activated in about 20-25% of human breast cancer cases. Several drugs that target Her2/neu are used in the treatment of Her2-positive breast cancer, such as a monoclonal antibody to the extracellular portion of the receptor or small molecule kinase inhibitors, but resistance to these drugs has frequently been seen in patients. Better understanding of Her2/neu and the downstream signal transduction pathways it uses will provide improved treatment for breast cancer patients. Our lab studies signal transduction pathways in breast cancer using a variety of approaches. Proteomics is the large-scale identification and characterization of proteins and it can be used to provide deeper insights into these pathways by identifying novel proteins and sites of post-translational modifications. We have previously published a large proteomic study of Her2/neu signaling in cell lines and are currently working on performing proteomic experiments in animal models.

Areas of Clinical Interest

Breast cancer, HER2 positive breast cancer, oncology, medical oncology

Fingerprint Dive into the research topics where Ron Bose is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

the CONTROL Study Investigators, Sep 2020, In : Annals of Oncology. 31, 9, p. 1223-1230 8 p.

Research output: Contribution to journalArticle

Open Access
  • 1 Scopus citations

    Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

    Kurzrock, R., Bowles, D. W., Kang, H., Meric-Bernstam, F., Hainsworth, J., Spigel, D. R., Bose, R., Burris, H., Sweeney, C. J., Beattie, M. S., Blotner, S., Schulze, K., Cuchelkar, V. & Swanton, C., Mar 2020, In : Annals of Oncology. 31, 3, p. 412-421 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 4 Scopus citations

    Identifying ERBB2 activating mutations in HER2-negative breast cancer: Clinical impact of institute-wide genomic testing and enrollment in matched therapy trials

    Exman, P., Garrido-Castro, A. C., Hughes, M. E., Freedman, R. A., Li, T., Trippa, L., Bychkovsky, B. L., Barroso-Sousa, R., Di Lascio, S., MacKichan, C., Lloyd, M. R., Krevalin, M., Cerami, E., Merrill, M. S., Santiago, R., Crowley, L., Kuhnly, N., Files, J., Lindeman, N. I., MacConaill, L. E. & 10 others, Kumari, P., Tolaney, S. M., Krop, I. E., Bose, R., Johnson, B. E., Ma, C. X., Dillon, D. A., Winer, E. P., Wagle, N. & Lin, N. U., 2019, In : JCO Precision Oncology. 3

    Research output: Contribution to journalArticle

  • Imaging of HER2 with [ 89 Zr]pertuzumab in response to T-DM1 therapy

    Massicano, A. V. F., Lee, S., Crenshaw, B. K., Aweda, T. A., El Sayed, R., Super, I., Bose, R., Marquez-Nostra, B. V. & Lapi, S. E., May 2019, In : Cancer Biotherapy and Radiopharmaceuticals. 34, 4, p. 209-217 9 p.

    Research output: Contribution to journalArticle

  • 8 Scopus citations

    Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

    Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., Bose, R., Spigel, D. R., Beattie, M. S., Blotner, S., Stone, A., Schulze, K., Cuchelkar, V. & Hainsworth, J., Apr 2019, In : The Lancet Oncology. 20, 4, p. 518-530 13 p.

    Research output: Contribution to journalArticle

  • 54 Scopus citations